NASDAQ:ATHX Athersys (ATHX) Stock Forecast, Price & News $0.43 +0.07 (+19.33%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$0.38▼$0.4550-Day Range$0.28▼$0.8052-Week Range$0.26▼$2.76Volume839,180 shsAverage Volume274,411 shsMarket Capitalization$9.72 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Athersys MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,172.9% Upside$5.50 Price TargetShort InterestHealthy3.62% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 stars 3.5 Analyst's Opinion Consensus RatingAthersys has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Athersys has a forecasted upside of 1,172.9% from its current price of $0.43.Amount of Analyst CoverageAthersys has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.62% of the float of Athersys has been sold short.Short Interest Ratio / Days to CoverAthersys has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Athersys has recently decreased by 0.25%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAthersys does not currently pay a dividend.Dividend GrowthAthersys does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATHX. Previous Next 2.4 News and Social Media Coverage News SentimentAthersys has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Athersys this week, compared to 0 articles on an average week.Search InterestOnly 4 people have searched for ATHX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Athersys to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Athersys insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.03% of the stock of Athersys is held by insiders.Percentage Held by InstitutionsOnly 19.35% of the stock of Athersys is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Athersys is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Athersys is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Athersys (NASDAQ:ATHX) StockAthersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.Read More ATHX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATHX Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comAthersys Slumps as MultiStem Fails in Mid-Stage Study - Analyst BlogSeptember 25, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Athersys (NASDAQ:ATHX)September 29, 2023 | Tradewins (Ad)Successful Options Trading Begins With…Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month! September 6, 2023 | finance.yahoo.comGrant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney TransplantationAugust 25, 2023 | finance.yahoo.comIs Athersys Inc (ATHX) Significantly Overvalued?August 18, 2023 | marketwatch.comAthersys Shares Tumble 26% After Pricing Public OfferingAugust 18, 2023 | investorplace.comWhy Is Athersys (ATHX) Stock Down 36% Today?August 18, 2023 | seekingalpha.comAthersys shares slide on pricing $3.5 million stock offeringSeptember 29, 2023 | Tradewins (Ad)Successful Options Trading Begins With…Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month! August 18, 2023 | finance.yahoo.comAthersys, Inc. Announces Pricing of $3.5 Million Public OfferingAugust 16, 2023 | finance.yahoo.comAthersys Reports Second Quarter 2023 Financial Results and Business HighlightsAugust 11, 2023 | finance.yahoo.comAthersys Appoints Neema Mayhugh, PhD to its Board of DirectorsAugust 11, 2023 | bizjournals.comAthersys executives foresee catalysts that could ease its financial journeyJuly 31, 2023 | businesswire.comAthersys to Host Business Update Conference Call on August 9thJuly 30, 2023 | fool.comAthersys (NASDAQ: ATHX)June 1, 2023 | tmcnet.comPatient Enrollment Begins in Third and Final CohortJune 1, 2023 | finance.yahoo.comPatient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys’ MultiStem® Following Hemorrhagic TraumaMay 23, 2023 | msn.comAthersys restructures debt with supplier, prioritizing multi-stem for stroke treatmentMay 23, 2023 | finance.yahoo.comAthersys Restructures Debt with SupplierMay 18, 2023 | bizjournals.comAthersys cuts quarterly loss as restructuring takes holdMay 18, 2023 | finance.yahoo.comAthersys Reports First Quarter 2023 Financial Results and Business HighlightsMay 8, 2023 | finance.yahoo.comAthersys to Participate in Three Upcoming ConferencesMay 1, 2023 | finance.yahoo.comAthersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care ConferenceApril 21, 2023 | finance.yahoo.comAthersys to Participate in The American Society for Neural Therapy and Repair Annual ConferenceApril 19, 2023 | finance.yahoo.comAthersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private PlacementApril 18, 2023 | finance.yahoo.comAthersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private PlacementApril 12, 2023 | businesswire.comAthersys to Host Business Update Conference Call on April 20 thSee More Headlines Receive ATHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter. Email Address ATHX Company Calendar Last Earnings8/16/2023Today9/29/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATHX CUSIPN/A CIK1368148 Webwww.athersys.com Phone(216) 431-9900Fax216-361-9495Employees24Year Founded1995Price Target and Rating Average Stock Price Forecast$5.50 High Stock Price Forecast$5.50 Low Stock Price Forecast$5.50 Forecasted Upside/Downside+1,207.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,530,000.00 Net Margins-1,362.14% Pretax Margin-32,469.17% Return on EquityN/A Return on Assets-198.80% Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick Ratio0.09 Sales & Book Value Annual Sales$5.32 million Price / Sales1.78 Cash FlowN/A Price / Cash FlowN/A Book Value($1.33) per share Price / Book-0.32Miscellaneous Outstanding Shares22,500,000Free Float22,494,000Market Cap$9.46 million OptionableOptionable Beta-0.74 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Daniel A. Camardo M.B.A. (Age 54)CEO, Sec., Principal Accounting Officer & Director Comp: $796.81kMs. Z. Kasey Rosado (Age 49)Interim Chief Financial Officer Comp: $1.51MMs. Maia A. Hansen M.B.A. (Age 54)M.S., Chief Operating Officer Comp: $962.57kSenthil Ranganathan Ph.D.VP of Technical OperationsMr. David Russ M.B.A.VP of Supply Chain, Fin. & Admin.Dr. Manal Morsy M.B.A.M.D., PH.D., Exec. VP & Head of Global Regulatory AffairsDr. Robert Mays Ph.D.Exec. VP, Head of Regenerative Medicine & Neuroscience ProgramsMr. Rakesh Ramachandran MSHead of Information Technology & Communications and VPDr. Sarah Busch Ph.D.VP of Regenerative Medicine & Head of Bus. Devel.Ms. Ellen GurleyMang. of Corp. Communications and Investor RelationsMore ExecutivesKey CompetitorsPulmatrixNASDAQ:PULMAptorum GroupNASDAQ:APMBiodexa PharmaceuticalsNASDAQ:BDRXFlora GrowthNASDAQ:FLGCAdamis PharmaceuticalsNASDAQ:ADMPView All CompetitorsInstitutional OwnershipWalleye Capital LLCBought 8,100 shares on 8/15/2023Ownership: 0.000%Citadel Advisors LLCSold 2,408 shares on 8/15/2023Ownership: 0.000%Geode Capital Management LLCBought 76,297 shares on 8/11/2023Ownership: 0.842%Simplex Trading LLCSold 2,900 shares on 8/4/2023Ownership: 0.000%Values First Advisors Inc.Bought 96,967 shares on 8/2/2023Ownership: 0.613%View All Institutional Transactions ATHX Stock - Frequently Asked Questions Should I buy or sell Athersys stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATHX shares. View ATHX analyst ratings or view top-rated stocks. What is Athersys' stock price forecast for 2023? 1 analysts have issued 12-month target prices for Athersys' stock. Their ATHX share price forecasts range from $5.50 to $5.50. On average, they expect the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 1,207.7% from the stock's current price. View analysts price targets for ATHX or view top-rated stocks among Wall Street analysts. How have ATHX shares performed in 2023? Athersys' stock was trading at $0.84 at the start of the year. Since then, ATHX shares have decreased by 49.9% and is now trading at $0.4206. View the best growth stocks for 2023 here. When is Athersys' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our ATHX earnings forecast. How were Athersys' earnings last quarter? Athersys, Inc. (NASDAQ:ATHX) announced its earnings results on Wednesday, August, 16th. The biopharmaceutical company reported ($0.62) EPS for the quarter. The biopharmaceutical company earned $0.05 million during the quarter. When did Athersys' stock split? Shares of Athersys reverse split on the morning of Monday, August 29th 2022. The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What is William (B.J.) Lehmann's approval rating as Athersys' CEO? 1 employees have rated Athersys Chief Executive Officer William (B.J.) Lehmann on Glassdoor.com. William (B.J.) Lehmann has an approval rating of 100% among the company's employees. This puts William (B.J.) Lehmann in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 65.0% of employees surveyed would recommend working at Athersys to a friend. What other stocks do shareholders of Athersys own? Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Vaxart (VXRT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), T2 Biosystems (TTOO) and ADMA Biologics (ADMA). What is Athersys' stock symbol? Athersys trades on the NASDAQ under the ticker symbol "ATHX." How do I buy shares of Athersys? Shares of ATHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Athersys' stock price today? One share of ATHX stock can currently be purchased for approximately $0.42. How much money does Athersys make? Athersys (NASDAQ:ATHX) has a market capitalization of $9.46 million and generates $5.32 million in revenue each year. The biopharmaceutical company earns $-72,530,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis. How can I contact Athersys? Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The official website for the company is www.athersys.com. The biopharmaceutical company can be reached via phone at (216) 431-9900, via email at ir@athersys.com, or via fax at 216-361-9495. This page (NASDAQ:ATHX) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.